Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SMMT 
Summit Therapeutics PLC (SMMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: SMMT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $34.69
1 Year Target Price $34.69
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 101.41% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.07B USD | Price to earnings Ratio - | 1Y Target Price 34.69 |
Price to earnings Ratio - | 1Y Target Price 34.69 | ||
Volume (30-day avg) 10 | Beta -1.03 | 52 Weeks Range 15.55 - 36.91 | Updated Date 09/16/2025 |
52 Weeks Range 15.55 - 36.91 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -142.53% | Return on Equity (TTM) -328.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13777196967 | Price to Sales(TTM) 753.9 |
Enterprise Value 13777196967 | Price to Sales(TTM) 753.9 | ||
Enterprise Value to Revenue 6425.28 | Enterprise Value to EBITDA -5.32 | Shares Outstanding 742846976 | Shares Floating 115839510 |
Shares Outstanding 742846976 | Shares Floating 115839510 | ||
Percent Insiders 84.34 | Percent Institutions 13.55 |
Upturn AI SWOT
Summit Therapeutics PLC
Company Overview
History and Background
Summit Therapeutics PLC, originally founded as Oxford BioMedica in 1995, rebranded to Summit Therapeutics. It has focused on developing innovative medicines targeting unmet needs in oncology.
Core Business Areas
- Oncology Drug Development: Focused on developing novel therapies for cancer treatment.
Leadership and Structure
Robert W. Duggan serves as the Chairman and CEO. The company operates with a structure common for biotech companies: research and development, clinical trials, and corporate functions.
Top Products and Market Share
Key Offerings
- Ivonacogene Sorafenpaz, Ridutrel: Ivonacogene Sorafenpaz (previously known as SGT-610) is their lead product candidate targeting solid tumors. Ridutrel targets cancer. Currently in clinical development. Market share is currently negligible as these are in development. Competitors are pharmaceutical companies with approved oncology therapies (e.g., Roche, Novartis, Pfizer).
Market Dynamics
Industry Overview
The oncology drug development industry is characterized by high risk, high reward, and intense competition. Personalized medicine and immunotherapies are key trends.
Positioning
Summit Therapeutics PLC is positioned as a smaller player focusing on innovation. Its competitive advantage relies on its novel drug candidates and development strategies.
Total Addressable Market (TAM)
The global oncology market is estimated to be around $200 billion. Summit Therapeutics' position within this TAM depends on the clinical success and market adoption of its products.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced leadership
- Strong intellectual property
Weaknesses
- Limited financial resources compared to larger pharma companies
- Reliance on clinical trial success
- Single product focus
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new oncology indications
- Positive clinical trial results
Threats
- Clinical trial failures
- Competition from established oncology therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- PFE
- NVS
- MRK
- BMY
- AZN
- GILD
Competitive Landscape
Summit Therapeutics PLC faces significant competition from larger, established pharmaceutical companies with more resources. Its success hinges on its innovative approaches and niche market focus.
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on successful clinical trials and partnerships.
Future Projections: Future growth is contingent on successful clinical trials for its drug candidates.
Recent Initiatives: Focus on clinical trial advancement of its lead drug candidates and strategic partnerships.
Summary
Summit Therapeutics PLC is a clinical-stage oncology company with promising therapies in development. Its success depends on favorable clinical trial results and the ability to secure partnerships. The company faces significant competition and financial constraints, requiring diligent execution of its development strategy.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Summit Therapeutics PLC
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2015-03-05 | Co-CEO & Executive Chairman Mr. Robert W. Duggan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 159 | Website https://www.smmttx.com |
Full time employees 159 | Website https://www.smmttx.com | ||
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.